



US government (USG) investment in global health R&D has delivered

\$38.3 million
to Iowa research institutions*

450+ new jobs
for Iowa†

Iowa's top global health R&D institutions by USG funding*

ORGANIZATION	FUNDING
University of Iowa	\$20.8 million
Iowa State University	\$17.5 million

Global health R&D at work in the Hawkeye State



RTI Fights NTDS

Iowa State University researchers are looking for solutions to schistosomiasis, a devastating disease caused by parasitic worms. The worms can live for years in the human bloodstream, laying eggs that cause organ damage and impaired development in children. The disease is found in tropical areas, especially in poor communities without safe drinking water and adequate sanitation. More than 200 million people per year require treatment for schistosomiasis. Only one drug is currently available to fight the disease, but the parasites show signs of resistance. The Iowa team is examining the worm's genome for vulnerability that could be targeted with new drug treatments. They're also focusing on gene editing to make the worms sterile, thereby eliminating their ability to inflict damage.

Neglected diseases in Iowa‡

HIV diagnoses	1,032
Tuberculosis cases	412
West Nile cases	170
Malaria cases	88
Dengue cases	30


Iowa industry in global health R&D

Integrated DNA Technologies:

Coralville

Newlink Genetics: Ames

Iowa's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES*

89¢ of every dollar
the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

†Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.

‡Centers for Disease Control and Prevention: HIV diagnoses 2008–2016, Tuberculosis cases 2008–2016, West Nile virus disease cases 2008–2016, Malaria cases 2008–2014, Dengue virus infection cases 2010–2016.

§Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

¶NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.